The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Open accessAbstract
Epilepsy is one of the most common neurological chronic disorders, with an estimated prevalence of 0. 5 – 1%. Currently, treatment options for epilepsy are predominantly based on the administration of symptomatic therapy. Most patients are able to achieve seizure freedom by the first two appropriate drug trials. Thus, patients who cannot reach a satisfactory response after that are defined as pharmacoresistant. However, despite the availability of more than 20 antiseizure medications (ASMs), about one-third of epilepsies remain drug-resistant. The heterogeneity of seizures and epilepsies, the coexistence of comorbidities, and the broad spectrum of efficacy, safety, and tolerability related to the ASMs, make the management of these patients actually challenging. In this review, we analyze the most relevant clinical and pathogenetic issues related to drug-resistant epilepsy, and then we discuss the current evidence about the use of available ASMs and the alternative non-pharmacological approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S., & French, J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02397.x · Cited by 4,877
Lefaucheur, J.-P., Aleman, A., Baeken, C., Benninger, D. H., Brunelin, J., Di Lazzaro, V., Filipović, S. R., Grefkes, C., Hasan, A., Hummel, F. C., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.11.002 · Cited by 2,382
Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., et al. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.05.021 · Cited by 2,119
Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy
Fisher, R., Salanova, V., Witt, T., Worth, R., Henry, T., Gross, R., Oommen, K., Osorio, I., Nazzaro, J., Labar, D., et al. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02536.x · Cited by 1,918
Dalgleish, T. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1432 · Cited by 1,849
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Chen, Z., Brodie, M. J., Liew, D., & Kwan, P. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3949 · Cited by 1,514
Kwan, P., Schachter, S. C., & Brodie, M. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004418 · Cited by 1,052
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015 · cited 1×
“A first phase II, randomized, double-blind, placebo-controlled trial of CBD was performed on children and adolescents with DS (90, 91); then two phase III, randomized, double-blind, placebo-controlled trials demonstrated CBD effectiveness and safety as an adjunctive drug in patients with LGS, especially for the contro…”
BackgroundPatterns of treatment response in newly diagnosed epilepsy
Brodie, M. J., Barry, S. J. E., Bamagous, G. A., Norrie, J. D., & Kwan, P. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563b19 · Cited by 931
Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., Lyons, P. D., Taylor, A., Roberts, C., Sommerville, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30136-3 · Cited by 905
Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy
Salanova, V., Witt, T., Worth, R., Henry, T. R., Gross, R. E., Nazzaro, J. M., Labar, D., Sperling, M. R., Sharan, A., Sandok, E., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001334 · Cited by 821
Comorbidities of epilepsy: current concepts and future perspectives
Keezer, M. R., Sisodiya, S. M., & Sander, J. W. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00225-2 · Cited by 778
Glauser, T., Ben‐Menachem, E., Bourgeois, B., Cnaan, A., Guerreiro, C., Kälviäinen, R., Mattson, R., French, J. A., Perucca, E., Tomson, T., et al. (2013) · Epilepsia · doi:10.1111/epi.12074 · Cited by 721
Arroyo, S., Rumià, J., Martínez, I., & Ribalta, T. (1998) · PubMed · Cited by 652
Heck, C. N., King‐Stephens, D., Massey, A. D., Nair, D. R., Jobst, B. C., Barkley, G. L., Salanova, V., Cole, A. J., Smith, M. C., Gwinn, R. P., et al. (2014) · Epilepsia · doi:10.1111/epi.12534 · Cited by 651
Long-term treatment with responsive brain stimulation in adults with refractory partial seizures
Bergey, G. K., Morrell, M. J., Mizrahi, E. M., Goldman, A., King-Stephens, D., Nair, D., Srinivasan, S., Jobst, B., Gross, R. E., Shields, D. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001280 · Cited by 634
Fregni, F., El-Hagrassy, M. M., Pacheco-Barrios, K., Carvalho, S., Leite, J., Simis, M., Brunelin, J., Nakamura-Palacios, E. M., Marangolo, P., Venkatasubramanian, G., et al. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa051 · Cited by 605
The epidemiology of drug‐resistant epilepsy: A systematic review and meta‐analysis
Kalilani, L., Sun, X., Pelgrims, B., Noack‐Rink, M., & Villanueva, V. (2018) · Epilepsia · doi:10.1111/epi.14596 · Cited by 587
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy
Nair, D. R., Laxer, K. D., Weber, P. B., Murro, A. M., Park, Y. D., Barkley, G. L., Smith, B. J., Gwinn, R. P., Doherty, M. J., Noe, K. H., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010154 · Cited by 490
Wang, J., Lin, Z.-J., Liu, L., Xu, H.-Q., Shi, Y.-W., Yi, Y.-H., He, N., & Liao, W.-P. (2017) · Seizure · doi:10.1016/j.seizure.2016.11.030 · Cited by 487
Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms
Schmidt, D., & Löscher, W. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.54904.x · Cited by 482
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
Tang, F., Hartz, A. M. S., & Bauer, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00301 · Cited by 482
Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304
French, J. A., Krauss, G. L., Biton, V., Squillacote, D., Yang, H., Laurenza, A., Kumar, D., Rogawski, M. A., Campanille, V., Floridia, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635735 · Cited by 479
Sisodiya, S. M., Lin, W. ‐., Harding, B. N., Squier, M. V., & Thom, M. (2002) · Brain · doi:10.1093/brain/awf002 · Cited by 479
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Devinsky, O., Patel, A. D., Thiele, E. A., Wong, M. H., Appleton, R., Harden, C. L., Greenwood, S., Morrison, G., Sommerville, K., On behalf of the GWPCARE1 Part A Study Group, et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005254 · Cited by 458
Picot, M., Baldy‐Moulinier, M., Daurès, J., Dujols, P., & Crespel, A. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01579.x · Cited by 455
Morris, G. L., Gloss, D., Buchhalter, J., Mack, K. J., Nickels, K., & Harden, C. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a393d1 · Cited by 450
Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures
Krauss, G. L., Serratosa, J. M., Villanueva, V., Endziniene, M., Hong, Z., French, J., Yang, H., Squillacote, D., Edwards, H. B., Zhu, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318254473a · Cited by 431
French, J. A., Krauss, G. L., Steinhoff, B. J., Squillacote, D., Yang, H., Kumar, D., & Laurenza, A. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03638.x · Cited by 423
Wilmshurst, J. M., Gaillard, W. D., Vinayan, K. P., Tsuchida, T. N., Plouin, P., Van Bogaert, P., Carrizosa, J., Elia, M., Craiu, D., Jovic, N. J., et al. (2015) · Epilepsia · doi:10.1111/epi.13057 · Cited by 418
Molecular and cellular mechanisms of pharmacoresistance in epilepsy
Remy, S., & Beck, H. (2006) · Brain · doi:10.1093/brain/awh682 · Cited by 406
Ketogenic diets for drug-resistant epilepsy
Martin-McGill, K. J., Bresnahan, R., Levy, R. G., & Cooper, P. N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001903.pub5 · Cited by 402
Lagae, L., Sullivan, J., Knupp, K., Laux, L., Polster, T., Nikanorova, M., Devinsky, O., Cross, J. H., Guerrini, R., Talwar, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32500-0 · Cited by 384
Lamotrigine substitution study: evidence for synergism with sodium valproate?
Brodie, M. J., & Yuen, A. W. C. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(96)01007-8 · Cited by 379
Ben-Menachem, E., Hamberger, A., Hedner, T., Hammond, E. J., Uthman, B. M., Slater, J., Treig, T., Stefan, H., Ramsay, R. E., Wernicke, J. F., et al. (1995) · Epilepsy Research · doi:10.1016/0920-1211(94)00083-9 · Cited by 376
Idiosyncratic Adverse Reactions to Antiepileptic Drugs
Zaccara, G., Franciotta, D., & Perucca, E. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01041.x · Cited by 364
Krauss, G. L., Klein, P., Brandt, C., Lee, S. K., Milanov, I., Milovanovic, M., Steinhoff, B. J., & Kamin, M. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30399-0 · Cited by 342
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial
French, J. A., Krauss, G. L., Wechsler, R. T., Wang, X.-F., DiVentura, B., Brandt, C., Trinka, E., O'Brien, T. J., Laurenza, A., Patten, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001930 · Cited by 329 · cited 1×
“The approved use of PER for primary generalized tonic-clonic (PGTC) seizures was based on a double-blind randomized placebo-controlled trial (study 332) that provides ILAE Class I evidence of reduced seizure frequency in refractory idiopathic generalized epilepsy (study 332) (85, 86).”
MethodGeller, E. B., Skarpaas, T. L., Gross, R. E., Goodman, R. R., Barkley, G. L., Bazil, C. W., Berg, M. J., Bergey, G. K., Cash, S. S., Cole, A. J., et al. (2017) · Epilepsia · doi:10.1111/epi.13740 · Cited by 310
Epilepsy after the first drug fails: substitution or add-on?
Kwan, P., & Brodie, M. J. (2000) · Seizure · doi:10.1053/seiz.2000.0442 · Cited by 306
Deep brain stimulation for drug‐resistant epilepsy
Li, M. C. H., & Cook, M. J. (2018) · Epilepsia · doi:10.1111/epi.13964 · Cited by 293
Wirrell, E. C., Laux, L., Donner, E., Jette, N., Knupp, K., Meskis, M. A., Miller, I., Sullivan, J., Welborn, M., & Berg, A. T. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.01.025 · Cited by 283
Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy
Kwan, P., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.31904.x · Cited by 281
The clinical impact of pharmacogenetics on the treatment of epilepsy
Löscher, W., Klotz, U., Zimprich, F., & Schmidt, D. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01716.x · Cited by 281
Valentín, A., García Navarrete, E., Chelvarajah, R., Torres, C., Navas, M., Vico, L., Torres, N., Pastor, J., Selway, R., Sola, R. G., et al. (2013) · Epilepsia · doi:10.1111/epi.12352 · Cited by 272
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
Devinsky, O., Nabbout, R., Miller, I., Laux, L., Zolnowska, M., Wright, S., & Roberts, C. (2019) · Epilepsia · doi:10.1111/epi.14628 · Cited by 271
Miller, I., Scheffer, I. E., Gunning, B., Sanchez-Carpintero, R., Gil-Nagel, A., Perry, M. S., Saneto, R. P., Checketts, D., Dunayevich, E., Knappertz, V., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0073 · Cited by 267
Managing drug-resistant epilepsy: challenges and solutions
Dalic, L., & Cook, M. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84852 · Cited by 258
Nabbout, R., Mistry, A., Zuberi, S., Villeneuve, N., Gil-Nagel, A., Sanchez-Carpintero, R., Stephani, U., Laux, L., Wirrell, E., Knupp, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4113 · Cited by 251
Inflammatory pathways of seizure disorders
Marchi, N., Granata, T., & Janigro, D. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.11.002 · Cited by 241
Cognitive and neurodevelopmental comorbidities in paediatric epilepsy
Nickels, K. C., Zaccariello, M. J., Hamiwka, L. D., & Wirrell, E. C. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.98 · Cited by 234
Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy
(2000) · Epilepsia · doi:10.1111/j.1499-1654.2000.001597.x · Cited by 225
Successful use of fenfluramine as an add‐on treatment for Dravet syndrome
Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P. G., & Lagae, L. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03495.x · Cited by 210 · cited 1×
“A group of child neurologists in Belgium continued to use FFA in children with DS at lower doses, showing encouraging results (103).”
ResultSake, J.-K., Hebert, D., Isojärvi, J., Doty, P., De Backer, M., Davies, K., Eggert-Formella, A., & Zackheim, J. (2010) · CNS Drugs · doi:10.2165/11587550-000000000-00000 · Cited by 197
Canevini, M. P., De Sarro, G., Galimberti, C. A., Gatti, G., Licchetta, L., Malerba, A., Muscas, G., La Neve, A., Striano, P., Perucca, E., et al. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02520.x · Cited by 192
Self-citationNeuroinflammatory targets and treatments for epilepsy validated in experimental models
Aronica, E., Bauer, S., Bozzi, Y., Caleo, M., Dingledine, R., Gorter, J. A., Henshall, D. C., Kaufer, D., Koh, S., Löscher, W., et al. (2017) · Epilepsia · doi:10.1111/epi.13783 · Cited by 191
Vagus nerve stimulation for partial seizures
Panebianco, M., Rigby, A., Weston, J., & Marson, A. G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002896.pub2 · Cited by 189
Balestrini, S., & Sisodiya, S. M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.014 · Cited by 186
Combination Therapy in Epilepsy: When and What to Use
Kwan, P., & Brodie, M. J. (2006) · Drugs · doi:10.2165/00003495-200666140-00004 · Cited by 183
Remission and relapse in a drug-resistant epilepsy population followed prospectively
Callaghan, B., Schlesinger, M., Rodemer, W., Pollard, J., Hesdorffer, D., Allen Hauser, W., & French, J. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02929.x · Cited by 176
Improved outcomes with earlier surgery for intractable frontal lobe epilepsy
Simasathien, T., Vadera, S., Najm, I., Gupta, A., Bingaman, W., & Jehi, L. (2013) · Annals of Neurology · doi:10.1002/ana.23862 · Cited by 165
Carbamazepine Toxicity with Lamotrigine: Pharmacokinetic or Pharmacodynamic Interaction?
Besag, F. M. C., Berry, D. J., Pool, F., Newbery, J. E., & Subel, B. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01356.x · Cited by 161
Refractory epilepsy: a progressive, intractable but preventable condition?
Kwan, P., & Brodie, M. J. (2002) · Seizure · doi:10.1053/seiz.2002.0593 · Cited by 161
Anderson, L. L., Absalom, N. L., Abelev, S. V., Low, I. K., Doohan, P. T., Martin, L. J., Chebib, M., McGregor, I. S., & Arnold, J. C. (2019) · Epilepsia · doi:10.1111/epi.16355 · Cited by 159
Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial
Klinkenberg, S., Aalbers, M. W., Vles, J. S. H., Cornips, E. M. J., Rijkers, K., Leenen, L. A. M., Kessels, F., Aldenkamp, A. P., & Majoie, M. (2012) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2012.04305.x · Cited by 152
Valproate-Ethosuximide Combination Therapy for Refractory Absence Seizures
Rowan, A. J., Meijer, J. W. A., de Beer-Pawlikowski, N. K. B., van der Geest, P., & Meinardi, H. (1983) · Archives of Neurology · doi:10.1001/archneur.1983.04050120047006 · Cited by 149
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 149
Louis, E. K. S. (2009) · Current Neuropharmacology · doi:10.2174/157015909788848929 · Cited by 148
Boon, P., Cock, E. D., Mertens, A., & Trinka, E. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000534 · Cited by 148
A Review of Neurostimulation for Epilepsy in Pediatrics
Starnes, K., Miller, K. J., Wong‐Kisiel, L. C., & Lundstrom, B. N. (2019) · Brain Sciences · doi:10.3390/brainsci9100283 · Cited by 144
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2018) · Epilepsia · doi:10.1111/epi.14557 · Cited by 137
Margolis, J. M., Chu, B. C., Wang, Z. J., Copher, R. M., & Cavazos, J. E. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.808 · Cited by 136
Dravet syndrome: Treatment options and management of prolonged seizures
Cross, J. H., Caraballo, R. H., Nabbout, R., Vigevano, F., Guerrini, R., & Lagae, L. G. (2019) · Epilepsia · doi:10.1111/epi.16334 · Cited by 132
Identifying mutations in epilepsy genes: Impact on treatment selection
Perucca, P., & Perucca, E. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.03.001 · Cited by 131
Pharmacoresistant epilepsy: From pathogenesis to current and emerging therapies
Pati, S. B. B., & Alexopoulos, A. V. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.09061 · Cited by 130
A new hypothesis of drug refractory epilepsy: Neural network hypothesis
Fang, M., Xi, Z., Wu, Y. F., & Wang, X. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.02.039 · Cited by 128
A Practical Guide to Treatment of Childhood Absence Epilepsy
Kessler, S. K., & McGinnis, E. L. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00325-x · Cited by 122
Fisher, B., DesMarteau, J. A., Koontz, E. H., Wilks, S. J., & Melamed, S. E. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.610379 · Cited by 120
Yang, D., Wang, Q., Xu, C., Fang, F., Fan, J., Li, L., Du, Q., Zhang, R., Wang, Y., Lin, Y., et al. (2019) · Brain stimulation · doi:10.1016/j.brs.2019.09.006 · Cited by 118
Lasoń, W., Dudra-Jastrzębska, M., Rejdak, K., & Czuczwar, S. J. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70497-2 · Cited by 117
Krauss, G. L., Perucca, E., Ben‐Menachem, E., Kwan, P., Shih, J. J., Clément, J., Wang, X., Bagul, M., Gee, M., Zhu, J., et al. (2014) · Epilepsia · doi:10.1111/epi.12643 · Cited by 111
Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation
Terrone, G., Salamone, A., & Vezzani, A. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170926113754 · Cited by 111
The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs
Rogawski, M. A. (2013) · Epilepsia · doi:10.1111/epi.12182 · Cited by 110
Schoonjans, A., Paelinck, B. P., Marchau, F., Gunning, B. W., Gammaitoni, A. R., Galer, B. S., Lagae, L. G., & Ceulemans, B. (2016) · European Journal of Neurology · doi:10.1111/ene.13195 · Cited by 110
Understanding the Delay Before Epilepsy Surgery: Who Develops Intractable Focal Epilepsy and When?
Berg, A. T. (2004) · CNS Spectrums · doi:10.1017/s109285290000849x · Cited by 108
Brivaracetam add-on for refractory focal epilepsy
Lattanzi, S., Cagnetti, C., Foschi, N., Provinciali, L., & Silvestrini, M. (2016) · Neurology · doi:10.1212/wnl.0000000000002545 · Cited by 106
Epilepsy treatment in adults and adolescents: Expert opinion, 2016
Shih, J. J., Whitlock, J. B., Chimato, N. T., Vargas, E. R., Karceski, S. C., & Frank, R. D. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.018 · Cited by 106
Vagus nerve stimulation for drug-resistant epilepsy
Pérez‐Carbonell, L., Faulkner, H. J., Higgins, S. E., Koutroumanidis, M., & Leschziner, G. D. (2019) · Practical Neurology · doi:10.1136/practneurol-2019-002210 · Cited by 103
Cannabidiol efficacy and clobazam status: A systematic review and meta‐analysis
Lattanzi, S., Trinka, E., Striano, P., Zaccara, G., Giovane, C. D., Nardone, R., Silvestrini, M., & Brigo, F. (2020) · Epilepsia · doi:10.1111/epi.16546 · Cited by 97
Self-citationAntiepileptic Drug Therapy in Patients with Drug-Resistant Epilepsy
Park, K. M., Kim, S. E., & Lee, B. I. (2019) · Journal of Epilepsy Research · doi:10.14581/jer.19002 · Cited by 96
Lamotrigine and topiramate may be a useful combination
Stephen, L. J., Sills, G. J., & Brodie, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60613-7 · Cited by 95
Monotherapy or Polytherapy for Epilepsy Revisited: A Quantitative Assessment
Lammers, M. W., Hekster, Y. A., Keyser, A., Meinardi, H., Renier, W. O., & van Lier, H. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb00484.x · Cited by 90
Examining the Clinical Utility of Lacosamide: Pooled Analyses of Three Phase II/III Clinical Trials
Chung, S. S., Ben‐Menachem, E., Sperling, M. R., Rosenfeld, W. E., Fountain, N. B., Benbadis, S. R., Hebert, D., Isojärvi, J. I. T., & Doty, P. (2010) · CNS Drugs · doi:10.2165/11586830-000000000-00000 · Cited by 89
The pharmacological management of Lennox-Gastaut syndrome and critical literature review
Verrottı, A., Striano, P., Iapadre, G., Zagaroli, L., Bonanni, P., Coppola, G., Elia, M., Mecarelli, O., Franzonı, E., Liso, P. D., et al. (2018) · Seizure · doi:10.1016/j.seizure.2018.10.016 · Cited by 89
Self-citationVerrotti, A., Tambucci, R., Francesco, L. D., Pavone, P., Iapadre, G., Altobelli, E., Matricardi, S., Farello, G., & Belcastro, V. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1707668 · Cited by 89
Self-citationEpilepsia resistente a fármacos. Concepto y alternativas terapéuticas
Gonzalez, F. L., Osorio, X. R., Rein, A. G.-N., Martínez, M., Fernández, J. S., Haba, V. V., Pedraza, A. J. D., & Cerdá, J. M. M. (2014) · Neurología · doi:10.1016/j.nrl.2014.04.012 · Cited by 84
Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome
Schoonjans, A., Lagae, L. G., & Ceulemans, B. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615607726 · Cited by 83
Diet in the Treatment of Epilepsy: What We Know So Far
Verrottı, A., Iapadre, G., Francesco, L. D., Zagaroli, L., & Farello, G. (2020) · Nutrients · doi:10.3390/nu12092645 · Cited by 83
Drug-resistant epilepsy: Definition and treatment alternatives
González, F. J. L., Osorio, X. R., Rein, A. G.-N., Martínez, M., Fernández, J. S., Haba, V. V., Pedraza, A. J. D., & Cerdá, J. M. M. (2015) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.04.002 · Cited by 79
Old versus New: Why Do We Need New Antiepileptic Drugs?
Lee, S. K. (2014) · Journal of Epilepsy Research · doi:10.14581/jer.14010 · Cited by 79
Seizure-related injury and death
Nei, M., & Bagla, R. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0051-1 · Cited by 73
Lagae, L. G., Schoonjans, A., Gammaitoni, A. R., Galer, B. S., & Ceulemans, B. (2018) · Epilepsia · doi:10.1111/epi.14540 · Cited by 72
Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
Devinsky, O., Thiele, E. A., Wright, S., Checketts, D., Morrison, G., Dunayevich, E., & Knappertz, V. A. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13305 · Cited by 72
Low and High Frequency Hippocampal Stimulation for Drug-Resistant Mesial Temporal Lobe Epilepsy
Lim, S., Lee, C.-Y., Lee, S., Tu, P., Chang, B., Lee, C., Cheng, M.-Y., Chang, C., Tseng, W.-E. J., Hsieh, H., et al. (2016) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12435 · Cited by 71
Brigo, F., Ausserer, H., Tezzon, F., & Nardone, R. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.03.010 · Cited by 67
Anti-seizure medications for Lennox-Gastaut syndrome
Brigo, F., Jones, K. L., Eltze, C. M., & Matricardi, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003277.pub4 · Cited by 63
Self-citationPolytherapy in epilepsy: the experimental evidence
Czuczwar, S. J., & Borowicz, K. K. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(02)00181-x · Cited by 62
Electrical stimulation for drug-resistant epilepsy: an evidence-based analysis.
Chambers, A., & Bowen, J. M. (2013) · Europe PMC (PubMed Central) · Cited by 52
Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide
Brodie, M. J. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0678-x · Cited by 52
Lai, W. W., Galer, B. S., Wong, P. C., Farfel, G. M., Pringsheim, M., Keane, M. G., & Agarwal, A. (2020) · Epilepsia · doi:10.1111/epi.16638 · Cited by 52
Medical therapy of epilepsy: When to initiate treatment and when to combine?
Brodie, M. J. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0735-x · Cited by 43
Should men be screened and treated for postnatal depression?
Nazareth, I. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.183 · Cited by 43
Understanding Childhood Neuroimmune Diseases of the Central Nervous System
Matricardi, S., Farello, G., Savasta, S., & Verrotti, A. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00511 · Cited by 42
Self-citationResponsive Neurostimulation for the Treatment of Epilepsy
Matias, C. M., Sharan, A. D., & Wu, C. (2019) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.12.006 · Cited by 41
Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome
Balagura, G., Cacciatore, M., Grasso, E. A., Striano, P., & Verrottı, A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00755-z · Cited by 41
Self-citationLattanzi, S., Trinka, E., Russo, E., et al. (2019) · Drugs of today · doi:10.1358/dot.2019.55.3.2909248 · Cited by 39
Operto, F., Matricardi, S., Pastorino, G., Verrotti, A., & Coppola, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.578396 · Cited by 39
Self-citationMonitoring And Managing Depression In Adolescents With Epilepsy: Current Perspectives
Coppola, G., Operto, F. F., Matricardi, S., & Verrotti, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s192714 · Cited by 36
Self-citationContin, M., Mohamed, S., Santucci, M., Lodi, M. A. M., Russo, E., Mecarelli, O., & CBD LICE Italy Study Group (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.637801 · Cited by 35
Verrotti, A., D’Alonzo, R., Rinaldi, V. E., Casciato, S., D’Aniello, A., & Gennaro, G. D. (2017) · World Journal of Pediatrics · doi:10.1007/s12519-017-0006-9 · Cited by 30
Self-citationEmerging drugs for the treatment of Dravet syndrome
Brigo, F., Striano, P., Balagura, G., & Belcastro, V. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1552937 · Cited by 28
Self-citationPotential role of brivaracetam in pediatric epilepsy
Verrottı, A., Grasso, E. A., Cacciatore, M., Matricardi, S., & Striano, P. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13347 · Cited by 26
Self-citationRefractory absence seizures: An Italian multicenter retrospective study
Franzonı, E., Matricardi, S., Pisa, V. D., Capovilla, G., Romeo, A., Tozzi, E., Pruna, D., Salerno, G. G., Zamponi, N., Accorsi, P., et al. (2015) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2015.07.008 · Cited by 25
Self-citationClinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy
Lee, B. I., Park, K. M., Kim, S. E., & Heo, K. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.106165 · Cited by 22
Inflammation in pediatric epilepsies: Update on clinical features and treatment options
Granata, T., Fusco, L., Matricardi, S., Tozzo, A., Janigro, D., & Nabbout, R. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107959 · Cited by 16
Self-citationNovel therapeutic options for Dravet and Lennox-Gastaut syndrome
Verrottı, A., & Striano, P. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1862651 · Cited by 6
Self-citation
Cited by
Nicotinic acetylcholine receptors in neurological and psychiatric diseases
Terry, A. V., Jones, K., & Bertrand, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106764 · Cited by 90
Vavers, E., Zvejniece, L., & Dambrova, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106771 · Cited by 30
Metadata
- Authors
- Fattorusso, A., Matricardi, S., Mencaroni, E., Dell'Isola, G. B., Di Cara, G., Striano, P., & Verrotti, A.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2021-06-22
- Volume
- 12
- Pages
- 674483-674483
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W3177289043
- Cited by
- 269
- References
- 133
- FWCI
- 28.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.